bluebird bio to Present at Investor Conferences in September Read more about bluebird bio to Present at Investor Conferences in September
bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies Read more about bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies
Wells Fargo Securities 2018 Healthcare Conference Read more about Wells Fargo Securities 2018 Healthcare Conference
bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer Read more about bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium Read more about bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium
bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference Read more about bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference
bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read more about bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia Read more about bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia